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regression model was used to determine difference of the number of hospitalization 
among groups of severity and health insurance. Costs were converted to $US using 
30.59 Thai-baht per $1US. Results: Among 1,982 patients included, the average age 
was 40.3±24.0 years with 60.7% male. A total of 1,936 patients were non-high risk 
patients, while 46 patients were high-risk patients. There were 1,293 patients under 
universal coverage schemes (UCS), 264 patients under social security schemes, and 
626 patients under civil servant medical benefit schemes (CSMBS). The average 
annual cost/patient was $598±871. In adjusted analyses, the health care cost of high-
risk patients was $67 higher than that of non-high risk patients (95% confidence 
interval (CI); $64–$69). The cost of patients under CSMBS was $109 (95%CI; $105-$113) 
higher than that of patients under UCS. ConClusions: The health care costs in 
a cohort of patients with asthma were substantial and were higher in high-risk 
patients and patients under CSMBS.
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objeCtives: This study aims to propose an appropriate statistical method to ana-
lyse the longitudinal health-related quality of life (HRQoL) data. Methods: This 
was a longitudinal HRQoL study conducted among new smear positive pulmonary 
tuberculosis (PTB) patients diagnosed at the chest clinic of Penang General Hospital 
between March 2010 and February 2011. Eligible patients (i.e., literate and 18 years 
and above) were asked to self-complete the SF-36v2 questionnaire (either in Malay, 
Mandarin, Tamil or English) at the start of the treatment, after the intensive phase 
and at the end of the treatment. The mean physical component summary (PCS) and 
mental component summary (MCS) scores, ranging from 47–53, were considered 
equivalent to the general population norms. Repeated measures ANOVA (with single 
imputations) and linear mixed model were used to analyse the data. Results: A 
total of 216 patients completed the questionnaire at the start of their treatment. 
Out of these, 177 and 153 completed the questionnaire at the second and third 
follow-ups, respectively. Throughout the treatment, the mean PCS and MCS scores 
for the patients were less than 47. In repeated measures ANOVA analysis, level of 
education, diabetes, being alcoholic and cough with sputum were the significant 
predictors of PCS, whereas none of the covariates explained a significant variance 
in the MCS scores. In linear mixed model, ethnicity, marital status, being a smoker, 
productive cough and ≥ 3 TB-related symptoms were the significant predictors of 
PCS. Similarly, covariates such as ethnicity, hypertension, being a smoker, monthly 
income ≥ 1000 MYR and ≥ 3 TB-related symptoms significantly explained variance 
in the MCS scores. ConClusions: The study’s findings indicated compromised 
health among the study participants even at the end of treatment. According to dif-
ferent findings obtained from both methods and the limited assumption in applying 
repeated measures ANOVA, linear mixed model was preferred to analyse this data.
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objeCtives: Stevens - Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) 
are two forms of life-threatening dermatologic condition. The syndromes are very 
severe. They require lots of health care resource. However, there is little informa-
tion about health care resource utilization and cost of managing SJS/TEN. Thus, 
this study aimed to quantify health care use and cost of managing this syndrome 
in Thailand. Methods: A retrospective study using an electronic health database 
from a 1000 bed- university-affiliated hospital in Thailand was undertaken. Patients 
who were admitted with SJS/TEN from 2002 to 2007 were included. The cost was 
determined using the ratio of cost-to-charge of the hospital for each year. The cost 
was converted to 2013 value by consumer price index. The cost was converted to US$ 
using 32.97 Thai-baht per 1 US$. Results: A total of 157 patients were included with 
56.1% of male. Average age of the patients was 45.3±23.0 years. Of those patients, 118 
patients were primarily diagnosed as SJS/TEN, while 39 patients were secondarily 
diagnosed as SJS/TEN. About 146 patients (93.0%) were diagnosed as SJS and the rest 
of them were diagnosed as TEN. The average length of stay (LOS) was 10.1±13.2 days 
for all patients. The LOS for primarily diagnosed patients was 6.8±4.8 days, while 
the LOS for secondarily diagnosed patients was 20.2±22.5 days. Most of patients 
(93.0%) were treated with systemic corticosteroids. Prednisolone was commonly 
used as an oral medication, while dexamethasone was usually used as an inject 
medication. The average cost of managing SJS/TEN for all patients was $1,012±2,563. 
The median cost was $342 (min-max; $11-$26,345). The average cost for primarily 
diagnosed patients was $519±724, while that for secondarily diagnosed patients was 
$2,536±4,713. ConClusions: Health care utilization and cost of managing SJS/TEN 
in Thailand were substantial. Policy makers may consider allocating resources to 
support the development of strategies to minimize preventable SJS/TEN.
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the incidence-based economic burden of asthma within lifetime horizon of around 
16,193 billion VND. ConClusions: Understanding the economic impact of asthma 
on society is fundamental to plan and implement relevant medical policies. The high 
incidence-based economic burden of asthma of around 16,193 billion VND should be 
considered to conduct the health care policies in Vietnam.
PRS10
econoMic buRden oF PediatRic atoPic deRMatitiS in aSia-PaciFic:  
a Review oF tHe liteRatuRe
Bhanegaonkar A.1, Qin L.1, Horodniceanu E.H.1, Ji X.1, Detzel P.2, Botteman M.3
1Pharmerit International, Bethesda, MD, USA, 2Nestlé Research Centre, 1000 Lausanne 26, 
Switzerland, 3Pharmerit US Bethesda, Bethesda, MD, USA
objeCtives: Atopic dermatitis (AD) is a chronic skin disease typically presenting in 
infancy. A literature review was conducted to identify pediatric AD cost estimates in 
Asia-Pacific (AP) countries. Methods: An electronic literature search was conducted 
in PubMed, Google scholar, and Asian electronic reference databases to identify stud-
ies reporting on pediatric AD cost estimates in AP countries. Open text search terms 
were used to maximize the sensitivity of the search strategy. These searches were 
supplemented by manual reviews of bibliographies of the articles reporting cost esti-
mates and discussions with AD experts. Costs were inflated and converted to 2013 
US dollars. Results: Annual AD costs per patient were identified in Australia (cross-
sectional survey of 48 parents of AD children; age 4 months-15 years; total costs for 
all, mild, moderate, and severe cases: $2,745; $925; $3,301; $4,907, respectively; direct 
costs only: $1,400; $636; $1,577; $2,420, respectively), South Korea (cross-sectional 
survey of 196 parents of AD patients; age < 12 years; visiting an allergy clinic; total: 
$3,522; direct: $1,253); Indonesia (model-based; age 0-6; urban; total: $743; direct: 
$740), Malaysia (model-based; age 0-6; urban; total: $576; direct: $398), Philippines 
(model-based; age 0-6; urban; total: $371; direct: $363), Singapore (model-based; age 
0-6; urban; total: $1,097; direct: $957), and Thailand (model and chart review of 3,502 
AD children; age 0-5; direct costs; all, mild, moderate, and severe AD: $199, $124 $415, 
$968, respectively). ConClusions: The economics of pediatric AD in AP has not 
been extensively studied. Based on available evidence, annual pediatric AD costs are 
generally high. Variations in cost estimates are due to between-study differences in 
country of analysis, types of costs included, severity of AD, and costing methodol-
ogy. Further evaluations of the AD costs and the cost-effectiveness of pediatric AD 
prevention strategies in AP countries are warranted.
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objeCtives: Children with a family history of atopic disease receiving cow’s milk 
formula (CMF) are at high risk of atopic dermatitis (AD). Modeling techniques were 
used to estimate the economic impact of AD among urban high-risk children in 
Malaysia, Indonesia, and Singapore. Methods: A cohort Markov model was devel-
oped to simulate the cumulative incidence and costs of AD in 3 cohorts (one per 
country) of urban, high-risk infants partially of completely fed with CMF in early 
infancy (months 0-4). AD incidence was from the GINI study, the largest/longest 
prospective experimental study of infant formula and AD in this population. AD 
treatment patterns and resource use assumptions were dervided from expert opin-
ion (n= 8). Costing of resource use was based on the respective countries’ prices. 
Key modeled outcomes included the overall and annual direct/indirect costs of 
AD (converted to 2013 US$) from diagnosis to age 6. Multivariate probabilistic sen-
sitivity analysis was uses to generate 95% confidence intervals (CI) around study 
outcomes. Results: The 6-year cumulative risk of AD was 38% (95% CI: 22%, 57%). 
The mean overall estimated AD costs/child developing AD was $2,492 (95% CI: $1,887, 
$3,509) in Malaysia, $3,217 (95% CI: $2,339, $4,717) in Indonesia, and $4,753 (95% CI: 
$3,438, $6,961) in Singapore. Expressed on an annual basis, the cost of AD per child 
developing AD was $576 (95% CI: $501, $650) in Malaysia, $743 (95% CI: $605, $876) in 
Indonesia, and $1,097 (95% CI: $900, $1,303) in Singapore. Most of these costs were 
direct costs for physician visits and pharmacologic treatments. ConClusions: By 
age 6, the total cumulative AD-related costs among high-risk urban infants who are 
fed with CMF in early infancy are estimated to range from $2,492 to $4,473. Annual 
AD costs range from $576 to $1,097. Cost-effective AD prevention strategies should 
be considered to reduce this burden.
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objeCtives: Asthma is a major health care problem. Understanding current pat-
terns of health care utilization is important. Several previous studies compared 
health care utilization and cost by severity and health insurance; however, they may 
not be applicable to Thailand. This study aimed to compare health care utilization 
and cost by asthma severity and type of health insurance in Thailand. Methods: 
A retrospective study using an electronic database was conducted in patients with 
asthma who visited a University-affiliated hospital during 2009-2011. The outcomes 
were health care utilization and costs of in-patient and out-patient care. We com-
pared outcomes between groups based on a proxy of severity (high vs. non-high 
risk of emergency department visit) and type of health insurance. Multivariable 
generalized linear regression model with log link function was used to determine 
the difference of average health care cost, while multivariable negative binomial 
